TESARO (TSRO) Price Target Cut to $146.00
TESARO (NASDAQ:TSRO) had its price target cut by Morgan Stanley from $156.00 to $146.00 in a report issued on Thursday. They currently have an overweight rating on the biopharmaceutical company’s stock.
A number of other research analysts also recently issued reports on TSRO. Jefferies Group reissued a hold rating and issued a $124.00 price target on shares of TESARO in a report on Friday, November 3rd. Cann reissued a buy rating and issued a $199.00 price target on shares of TESARO in a report on Tuesday, November 7th. Zacks Investment Research raised TESARO from a sell rating to a hold rating in a report on Wednesday, November 8th. HC Wainwright reissued a buy rating on shares of TESARO in a report on Wednesday, November 8th. Finally, Lake Street Capital reissued a buy rating and issued a $143.00 price target on shares of TESARO in a report on Thursday, November 9th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $133.39.
TESARO (NASDAQ TSRO) opened at $57.68 on Thursday. TESARO has a twelve month low of $52.20 and a twelve month high of $184.00. The stock has a market capitalization of $3,147.25, a P/E ratio of -6.28 and a beta of 1.40. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $85.24, for a total transaction of $70,663.96. Following the completion of the sale, the senior vice president now directly owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 40.50% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of TSRO. Nationwide Fund Advisors increased its position in shares of TESARO by 63.1% during the third quarter. Nationwide Fund Advisors now owns 61,500 shares of the biopharmaceutical company’s stock worth $7,940,000 after purchasing an additional 23,800 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new stake in shares of TESARO during the third quarter worth approximately $230,000. NJ State Employees Deferred Compensation Plan purchased a new stake in shares of TESARO during the third quarter worth approximately $775,000. Tocqueville Asset Management L.P. increased its position in shares of TESARO by 26.4% during the third quarter. Tocqueville Asset Management L.P. now owns 99,330 shares of the biopharmaceutical company’s stock worth $12,824,000 after purchasing an additional 20,750 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its position in shares of TESARO by 1.2% during the third quarter. State Board of Administration of Florida Retirement System now owns 49,054 shares of the biopharmaceutical company’s stock worth $6,333,000 after purchasing an additional 570 shares in the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.